Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jaume Capdevila

Showing results (111-120 of 192) with videos related to

Pageof 20
Sort By:
Advances in Therapy|November 23, 2016
Association of Performance Status and Pain in Metastatic Bone Pain Management in the Spanish Clinical SettingManuel Dómine Gómez, Nieves Díaz Fernández, Blanca Cantos Sánchez de Ibargüen, et al.
Revista Espanola De Patologia : Publicacion Oficial De La Sociedad Espanola De Anatomia Patologica Y De La Sociedad Espanola De Citologia|February 26, 2026
SEAP-GETNE consensus on prognostic and predictive molecular biomarkers in thyroid cancerIgnacio Ruz-Caracuel, Teresa Alonso-Gordoa, Susana Hernández, et al.
The Oncologist|June 30, 2021
Sunitinib and Evofosfamide (TH-302) in Systemic Treatment-Naïve Patients with Grade 1/2 Metastatic Pancreatic Neuroendocrine Tumors: The GETNE-1408 TrialEnrique Grande, Cristina Rodriguez-Antona, Carlos López, et al.
Journal of Neuroendocrinology|February 14, 2022
Development of a quality of life questionnaire for patients with pancreatic neuroendocrine tumours (the PANNET module)John K Ramage, Elizabeth Friend, Jordan Randell, et al.
Thyroid : Official Journal of the American Thyroid Association|December 8, 2023
Increased Progression-Free Survival with Cabozantinib Versus Placebo in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Irrespective of Prior Vascular Endothelial Growth Factor Receptor-Targeted Therapy and Tumor Histology: A Subgroup Analysis of the COSMIC-311 StudyJaume Capdevila, Jolanta Krajewska, Jorge Hernando, et al.
Endocrine-Related Cancer|June 3, 2024
Vandetanib in locally advanced or metastatic differentiated thyroid cancer refractory to radioiodine therapyMarcia S Brose, Jaume Capdevila, Rossella Elisei, et al.
Frontiers in Oncology|March 20, 2026
Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer after prior vascular endothelial growth factor receptor-targeted therapy (COSMIC-311): outcomes by BRAF statusMarcia S Brose, Bhumsuk Keam, Jolanta Krajewska, et al.
BMC Cancer|April 18, 2015
A randomized phase II study of capecitabine-based chemoradiation with or without bevacizumab in resectable locally advanced rectal cancer: clinical and biological featuresRamon Salazar, Jaume Capdevila, Berta Laquente, et al.
Thyroid : Official Journal of the American Thyroid Association|April 11, 2022
A Randomized, Double-Blind Noninferiority Study to Evaluate the Efficacy of the Cabozantinib Tablet at 60 mg Per Day Compared with the Cabozantinib Capsule at 140 mg Per Day in Patients with Progressive, Metastatic Medullary Thyroid CancerJaume Capdevila, Arkadiy Klochikhin, Sophie Leboulleux, et al.
European Journal of Cancer (Oxford, England : 1990)|December 28, 2020
Practical recommendations for the management of patients with gastroenteropancreatic and thoracic (carcinoid) neuroendocrine neoplasms in the COVID-19 eraVíctor Rodriguez-Freixinos, Jaume Capdevila, Marianne Pavel, et al.
Pageof 20

Showing results (111-120 of 192) with videos related to

Sort By:
Pageof 20
Advances in Therapy|November 23, 2016
Association of Performance Status and Pain in Metastatic Bone Pain Management in the Spanish Clinical SettingManuel Dómine Gómez, Nieves Díaz Fernández, Blanca Cantos Sánchez de Ibargüen, et al.
Revista Espanola De Patologia : Publicacion Oficial De La Sociedad Espanola De Anatomia Patologica Y De La Sociedad Espanola De Citologia|February 26, 2026
SEAP-GETNE consensus on prognostic and predictive molecular biomarkers in thyroid cancerIgnacio Ruz-Caracuel, Teresa Alonso-Gordoa, Susana Hernández, et al.
The Oncologist|June 30, 2021
Sunitinib and Evofosfamide (TH-302) in Systemic Treatment-Naïve Patients with Grade 1/2 Metastatic Pancreatic Neuroendocrine Tumors: The GETNE-1408 TrialEnrique Grande, Cristina Rodriguez-Antona, Carlos López, et al.
Journal of Neuroendocrinology|February 14, 2022
Development of a quality of life questionnaire for patients with pancreatic neuroendocrine tumours (the PANNET module)John K Ramage, Elizabeth Friend, Jordan Randell, et al.
Thyroid : Official Journal of the American Thyroid Association|December 8, 2023
Increased Progression-Free Survival with Cabozantinib Versus Placebo in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Irrespective of Prior Vascular Endothelial Growth Factor Receptor-Targeted Therapy and Tumor Histology: A Subgroup Analysis of the COSMIC-311 StudyJaume Capdevila, Jolanta Krajewska, Jorge Hernando, et al.
Endocrine-Related Cancer|June 3, 2024
Vandetanib in locally advanced or metastatic differentiated thyroid cancer refractory to radioiodine therapyMarcia S Brose, Jaume Capdevila, Rossella Elisei, et al.
Frontiers in Oncology|March 20, 2026
Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer after prior vascular endothelial growth factor receptor-targeted therapy (COSMIC-311): outcomes by BRAF statusMarcia S Brose, Bhumsuk Keam, Jolanta Krajewska, et al.
BMC Cancer|April 18, 2015
A randomized phase II study of capecitabine-based chemoradiation with or without bevacizumab in resectable locally advanced rectal cancer: clinical and biological featuresRamon Salazar, Jaume Capdevila, Berta Laquente, et al.
Thyroid : Official Journal of the American Thyroid Association|April 11, 2022
A Randomized, Double-Blind Noninferiority Study to Evaluate the Efficacy of the Cabozantinib Tablet at 60 mg Per Day Compared with the Cabozantinib Capsule at 140 mg Per Day in Patients with Progressive, Metastatic Medullary Thyroid CancerJaume Capdevila, Arkadiy Klochikhin, Sophie Leboulleux, et al.
European Journal of Cancer (Oxford, England : 1990)|December 28, 2020
Practical recommendations for the management of patients with gastroenteropancreatic and thoracic (carcinoid) neuroendocrine neoplasms in the COVID-19 eraVíctor Rodriguez-Freixinos, Jaume Capdevila, Marianne Pavel, et al.
Pageof 20